Clinical trials: Melanoma Stage
Melanoma (Skin)
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
- Trial name
- NCT00006249
- Testing
- pegylated interferon alfa, adjuvant therapy
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 1,258 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
This Phase II, multicenter, randomized, double-blind, placebo-controlled trial was designed to estimate the efficacy and characterize the safety of bevacizumab when combined with carboplatin + paclitaxel chemotherapy compared…
- Trial name
- BEAM (NCT00434252)
- Testing
- bevacizumab, carboplatin, paclitaxel
- Volunteers
- 214 people
- Sponsor
- Genentech, Inc.
Recurrent Melanoma, Stage IIA Melanoma
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT01748747
- Testing
- Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
This randomized phase II trial studies temozolomide to see how well it works compared to selumetinib in treating patients with melanoma of the eye that has spread to other places in the body.
- Conditions
- Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Ocular Melanoma With Extraocular Extension, Recurrent Uveal Melanoma
- Trial name
- NCT01143402
- Testing
- Dacarbazine, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 33 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasm Malignant
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Primary Objective: Part A - Monotherapy: To determine the maximum tolerated dose (MTD) of SAR260301 administered as monotherapy and either on a once or twice daily schedule, to patients with advanced solid tumors or lymphomas.
- Trial name
- NCT01673737
- Testing
- SAR260301, Vemurafenib
- Where
- 4 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Sanofi
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
A Clinical Trial of Patients With Melanoma
This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.
- Trial name
- NCT02915666
- Testing
- Digoxin Combination, Dabrafenib, Trametinib
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Unresectable Stage III or IV Malignant Melanoma
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
- Trial name
- NCT00261365
- Testing
- Ipilimumab
- Where
- 15 sites in United States, Denmark and 5 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer…
- Trial name
- NCT05933577
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 165 sites in United States, Argentina and 24 more
- Volunteers
- 1,089 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Melanoma (Skin)
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or…
- Trial name
- NCT00053781
- Testing
- perifosine
- Where
- 6 sites in Canada
- Volunteers
- 18 people
- Sponsor
- NCIC Clinical Trials Group
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Brain and Central Nervous System Tumors, Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who…
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00039572
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Sponsor
- Beth Israel Deaconess Medical Center
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Melanoma
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
This study is an open, single-center, multi-cohort phase Ib exploratory study, and 50 subjects are planned to be enrolled to observe the objective response rate of each subject.
- Trial name
- NCT05451407
- Testing
- TQB2618 injection, Toripalimab injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tumor Infiltrating Lymphocytes, Safety
A Study of GC101 TIL in Advanced Melanoma (BZ)
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 20 months.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Melanoma, Efficacy
- Trial name
- MIZAR-002 (NCT06120712)
- Testing
- GC101 TIL
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Chronic Myeloid Leukemia, Graft vs Host Disease
Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia
This study will investigate the safety and effectiveness of a new stem cell transplant procedure for treating chronic myelogenous leukemia (CML).
- Trial name
- NCT00001144
- Testing
- Modified bone marrow stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Melanoma
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling pathways are not redundant.
- Trial name
- NCT04756934
- Testing
- HX008, LP002
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.